Strategic Partnerships Clairity is expanding through collaborations, evidenced by a May 2026 partnership with MagView to scale AI-driven breast cancer risk assessment. This indicates potential sales leverage by targeting joint go-to-market opportunities, integration projects, and co-marketing with imaging software and hospital networks.

FDA Authorized Growth The company launched an FDA-authorized AI platform for breast cancer risk prediction and has completed a Series B financing of $43M. This signals strong validation and readiness for enterprise deals with health systems seeking compliant, scalable AI screening solutions.

Leadership Prestige Founder and CEO Connie Lehman is recognized on TIME100 Health List, boosting credibility with risk-averse healthcare buyers. Leverage executive visibility to open C-suite introductions, speaking engagements, and advisory roles that accelerate procurement conversations.

Clinical Validation Active participation in RSNA events and multi-center validation of an image-only AI model demonstrates a ready-to-purchase product with demonstrated clinical impact. Target hospital networks and radiology departments seeking evidence-backed, bias-reducing screening tools.

Financial Health & Scale With revenue in the lower-mid tens of millions and substantial funding, Clairity shows growth trajectory and resource capacity for enterprise deployments, customer success, and regional expansion. This supports multi-site contracts and long-term service agreements.